APA-viite

Lee, E. Q., Zhang, P., Wen, P. Y., Gerstner, E. R., Reardon, D. A., Aldape, K., . . . Mehta, M. P. (2015). ATCT-22 NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA. Neuro Oncol.

Chicago-tyylinen lähdeviittaus

Lee, Eudocia Q., et al. "ATCT-22 NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA." Neuro Oncol 2015.

MLA-viite

Lee, Eudocia Q., et al. "ATCT-22 NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA." Neuro Oncol 2015.

Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.